Professor Eric Morand is an internationally renowned academic physician-scientist. His career has focused on integrating clinical and laboratory science to advance patient outcomes in lupus.

Professor Morand founded a multinational consortium to design and validate new clinical endpoints, solving a decade-long impasse responsible for multiple failed trials. He led the breakthrough Phase 3 trial of the novel medicine anifrolumab, resulting in approval of only the second new medicine for lupus in 60 years and formally validating a key aspect of SLE pathogenesis. Professor Morand’s work identifying molecular targets for an alternative to steroids won the highest award of the Lupus Research Alliance, US.